Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Symptoms poor guide to testing for juvenile Huntington disease

The onset or presentation of specific clinical features that are typical of juvenile Huntington’s Disease (JHD) do not help physicians to diagnose the condition without genetic testing.

25 Feb 2013

TP PCR methodology may help streamline genetic testing for Huntington's

A new test may help to streamline genetic testing for Huntington Disease (HD) by generating accurate results, avoiding unnecessary additional testing, and improving turnaround time.

14 Feb 2013

Sangamo BioSciences fourth quarter revenues increase to $8.9 million

Sangamo BioSciences, Inc. today reported fourth quarter and full year 2012 financial results and accomplishments.

7 Feb 2013

Scientists receive honorary doctorate for research on Alzheimer's disease

On Monday 4 February, Dennis J. Selkoe and five other "brain teasers" will receive an honorary doctorate from the KU Leuven. The promoters for this honorary doctorate - VIB-KU Leuven professors Bart De Strooper and Wim Robberecht - will honor Dennis J. Selkoe for his scientific insights, but also for his relentless search for new medicines to treat Alzheimer's Disease and other conditions that cause severe damage in the brain.

4 Feb 2013

Researchers to develop new diagnostic tools and treatments for people with rare diseases

A multi-million Euro initiative is bringing together researchers from across the world to develop new diagnostic tools and new treatments for people with rare diseases and to connect research data in this area on a global scale.

25 Jan 2013

Clathrin protein may have a role in suppressing tumors

Newly published research by Indiana University structural biologist Joel Ybe and colleagues identifies a "topology switch" in the protein clathrin, the function of which may shed light on molecular processes involved in tumor suppression.

16 Jan 2013

Discussing patients’ end-of-life wishes ‘key’ in Huntington’s

Discussing end-of-life issues with patients suffering from Huntington’s disease is a key responsibility for physicians, say Dutch researchers.

9 Jan 2013

Scientists wrestle to understand why Huntington's can produce variable symptoms

Scientists have wrestled to understand why Huntington's disease, which is caused by a single gene mutation, can produce such variable symptoms. An authoritative review by a group of leading experts summarizes the progress relating cell loss in the striatum and cerebral cortex to symptom profile in Huntington's disease, suggesting a possible direction for developing targeted therapies.

9 Jan 2013

New technique can precisely add or delete genes in living cells

Researchers at MIT, the Broad Institute and Rockefeller University have developed a new technique for precisely altering the genomes of living cells by adding or deleting genes.

4 Jan 2013

JPND invites proposals from researchers to understand the underlying causes of neurodegenerative diseases

The EU Joint Programme - Neurodegenerative Disease Research (JPND) is inviting calls for proposals from research teams across Europe to increase understanding of the factors that put people at risk of developing neurodegenerative diseases (ND) such as Alzheimer's and also to evaluate health and social care strategies for people living with these debilitating illnesses.

10 Dec 2012

Novel SIRT2 inhibitor protects against neuronal damage in animal models of Huntington's

Treatment with a novel agent that inhibits the activity of SIRT2, an enzyme that regulates many important cellular functions, reduced neurological damage, slowed the loss of motor function and extended survival in two animal models of Huntington's disease.

30 Nov 2012

New way to protect neurons that express mutant huntingtin proteins

By using a model, researchers at the University of Montreal have identified and "switched off" a chemical chain that causes neurodegenerative diseases such as Huntington's disease, amyotrophic lateral sclerosis and dementia. The findings could one day be of particular therapeutic benefit to Huntington's disease patients. "We've identified a new way to protect neurons that express mutant huntingtin proteins," explained Dr. Alex Parker of the University of Montreal's Department of Pathology and Cell Biology and its affiliated CRCHUM Research Centre.

27 Nov 2012

Alnylam advances Tuschl II patent estate through the USPTO

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office has issued Notices of Allowance for three patent applications from the company's exclusively held Tuschl II patent estate.

26 Nov 2012

Hsp104 protein switches mechanism to break up amyloid versus disordered clumps

Several fatal brain disorders, including Parkinson's disease, are connected by the misfolding of specific proteins into disordered clumps and stable, insoluble fibrils called amyloid. Amyloid fibrils are hard to break up due to their stable, ordered structure. For example, α-synuclein forms amyloid fibrils that accumulate in Lewy Bodies in Parkinson's disease. By contrast, protein clumps that accumulate in response to environmental stress, such as heat shock, possess a less stable, disordered architecture.

20 Nov 2012

Feinstein seeks NDA approval for Fluorodopa F 18 PET scan to diagnose parkinsonian syndromes

The Feinstein Institute for Medical Research announced today the submission of a New Drug Application to the US Food and Drug Administration (FDA) for the Fluorodopa F 18 positron emission tomography (PET) scan used to diagnose parkinsonian syndromes.

15 Nov 2012

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of liver disease associated with AAT deficiency. These data were presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, "The Liver Meeting") held November 9-13, 2012 in Boston.

15 Nov 2012

University of Tübingen heads Neuromics consortium

Work has begun on Neuromics, a major project headed by Tübingen's Professor Olaf Riess; the project beat out ten other first-class applications to attain €12m euros in EU funding over five years.

8 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

Physician-researchers at Indiana University School of Medicine have reported the first effective therapy for a class of previously untreatable and potentially life-threatening tumors often found in children.

2 Nov 2012

XJB-5-131 compound suppresses symptoms of Huntington's in mice

There's new hope in the fight against Huntington's disease. A group of researchers that includes scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have designed a compound that suppresses symptoms of the devastating disease in mice.

2 Nov 2012

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Symptoms poor guide to testing for juvenile Huntington disease

TP PCR methodology may help streamline genetic testing for Huntington's

Sangamo BioSciences fourth quarter revenues increase to $8.9 million

Scientists receive honorary doctorate for research on Alzheimer's disease

Researchers to develop new diagnostic tools and treatments for people with rare diseases

Clathrin protein may have a role in suppressing tumors

Discussing patients’ end-of-life wishes ‘key’ in Huntington’s

Scientists wrestle to understand why Huntington's can produce variable symptoms

New technique can precisely add or delete genes in living cells

JPND invites proposals from researchers to understand the underlying causes of neurodegenerative diseases

Novel SIRT2 inhibitor protects against neuronal damage in animal models of Huntington's

New way to protect neurons that express mutant huntingtin proteins

Alnylam advances Tuschl II patent estate through the USPTO

Hsp104 protein switches mechanism to break up amyloid versus disordered clumps

Feinstein seeks NDA approval for Fluorodopa F 18 PET scan to diagnose parkinsonian syndromes

ALN RNAi therapeutic program represents novel approach for treatment of AAT deficiency

University of Tübingen heads Neuromics consortium

Alnylam third quarter 2012 revenues decrease to $16.8 million

Imatinib mesylate effectively treats children with neurofibromatosis type 1 tumors

XJB-5-131 compound suppresses symptoms of Huntington's in mice

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in